TR199802483T2 - Farmasötik terkipler. - Google Patents

Farmasötik terkipler.

Info

Publication number
TR199802483T2
TR199802483T2 TR1998/02483T TR9802483T TR199802483T2 TR 199802483 T2 TR199802483 T2 TR 199802483T2 TR 1998/02483 T TR1998/02483 T TR 1998/02483T TR 9802483 T TR9802483 T TR 9802483T TR 199802483 T2 TR199802483 T2 TR 199802483T2
Authority
TR
Turkey
Prior art keywords
continuous
pharmaceutical compositions
formulations
evacuation
thiazepine
Prior art date
Application number
TR1998/02483T
Other languages
English (en)
Inventor
Vinod Parikh Bhavnish
Joseph Timko Robert
Joseph Addicks William
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199802483(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of TR199802483T2 publication Critical patent/TR199802483T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Bu bulus, 11[ 4-[ 2-(-hidroksietoksi) etil ]-1-piperazinil ] dibenzo[ b, f ][ 1,4] tiazepin veya bunun farmasötik açidan kabul edilebilir bir tuzunu ihtiva eden sürekli tahliye edici formülasyonlar, bu sürekli tahliye edici formülasyonlari kullanalarak psikotik durumlari ve hiperaktiviteyi tedavi etme yöntemleri ve sürekli tahliye formülasyonlarini hazirlamaya mahsus bir yöntemle ilgilidir.
TR1998/02483T 1996-05-31 1997-05-27 Farmasötik terkipler. TR199802483T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9611328.7A GB9611328D0 (en) 1996-05-31 1996-05-31 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
TR199802483T2 true TR199802483T2 (tr) 1999-02-22

Family

ID=10794541

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02483T TR199802483T2 (tr) 1996-05-31 1997-05-27 Farmasötik terkipler.

Country Status (31)

Country Link
EP (1) EP0907364B1 (tr)
JP (5) JP2000511170A (tr)
CN (3) CN1511532A (tr)
AR (1) AR003662A1 (tr)
AT (1) ATE222105T1 (tr)
AU (1) AU727219B2 (tr)
BR (1) BR9709271A (tr)
CA (1) CA2251944C (tr)
CZ (1) CZ293760B6 (tr)
DE (1) DE69714739T2 (tr)
DK (1) DK0907364T3 (tr)
EG (1) EG24118A (tr)
ES (1) ES2182079T3 (tr)
GB (2) GB9611328D0 (tr)
HR (1) HRP970299B1 (tr)
HU (1) HU225152B1 (tr)
ID (1) ID18352A (tr)
IL (1) IL127222A (tr)
MY (1) MY120120A (tr)
NO (1) NO327801B1 (tr)
NZ (1) NZ332198A (tr)
PL (1) PL189887B1 (tr)
PT (1) PT907364E (tr)
RU (1) RU2201754C2 (tr)
SI (1) SI0907364T1 (tr)
SK (1) SK284131B6 (tr)
TR (1) TR199802483T2 (tr)
TW (1) TW550076B (tr)
UA (1) UA50772C2 (tr)
WO (1) WO1997045124A1 (tr)
ZA (1) ZA974735B (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050003001A1 (en) 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
US20100178333A1 (en) 2006-01-25 2010-07-15 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
EP1958617B1 (en) 2007-02-14 2010-09-08 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing quetiapine fumarate
WO2008110337A2 (en) 2007-03-09 2008-09-18 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
US20080287418A1 (en) * 2007-05-16 2008-11-20 Astrazeneca Ab Extended Release Compositions and Methods for Their Manufacture
PT2262486E (pt) * 2008-08-01 2013-03-27 Tovarna Zdravil D D Novo Mesto Krka Composição de quetiapina
EP2153834A3 (en) 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
US20110280938A1 (en) * 2009-01-05 2011-11-17 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
AR076907A1 (es) * 2009-05-13 2011-07-20 Wyeth Llc Composiciones con liberacion rapida de farmaco
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
CN102218042A (zh) * 2011-05-26 2011-10-19 青岛黄海制药有限责任公司 富马酸喹硫平组合物的缓释片剂及其制备方法
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
CN102406606B (zh) * 2011-11-29 2013-01-23 海南美大制药有限公司 富马酸喹硫平脂质体固体制剂
SI2822541T1 (sl) 2012-09-10 2018-12-31 Pharmathen S.A. Farmacevtski sestavek, ki obsega atipično antipsihotično sredstvo, in postopek za njegovo pripravo
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
CA2988918A1 (en) 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN106187873B (zh) * 2016-07-25 2019-11-05 宜春学院 一种芳胺基烷基氧类化合物及其制备方法
JP7128782B2 (ja) 2019-08-09 2022-08-31 信越化学工業株式会社 エアゾール食品用組成物、ヒドロキシプロピルメチルセルロース及びヒドロキシプロピルメチルセルロースの製造方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0266707B1 (en) * 1986-11-03 1992-01-22 Schering Corporation Sustained release labetalol tablet
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
JP3116970B2 (ja) * 1991-06-12 2000-12-11 三菱東京製薬株式会社 ペミロラストカリウムの徐放性製剤
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US5919491A (en) * 1994-05-13 1999-07-06 Smithkline Beecham Corporation Method and composition for increasing calcium uptake

Also Published As

Publication number Publication date
TW550076B (en) 2003-09-01
PL189887B1 (pl) 2005-10-31
ZA974735B (en) 1997-12-01
SK284131B6 (sk) 2004-09-08
CN1219879A (zh) 1999-06-16
MY120120A (en) 2005-09-30
HRP970299A2 (en) 1998-04-30
GB9611328D0 (en) 1996-08-07
NZ332198A (en) 2000-05-26
AU2967597A (en) 1998-01-05
CA2251944A1 (en) 1997-12-04
CN1142780C (zh) 2004-03-24
CZ293760B6 (cs) 2004-07-14
NO985539D0 (no) 1998-11-27
PT907364E (pt) 2002-12-31
CN101006985A (zh) 2007-08-01
JP2012031206A (ja) 2012-02-16
EP0907364A1 (en) 1999-04-14
UA50772C2 (uk) 2002-11-15
HUP9902194A2 (hu) 2000-02-28
RU2201754C2 (ru) 2003-04-10
SK163998A3 (en) 1999-05-07
PL330223A1 (en) 1999-05-10
CA2251944C (en) 2007-04-10
AU727219B2 (en) 2000-12-07
IL127222A (en) 2001-03-19
DK0907364T3 (da) 2002-11-11
JP2007119495A (ja) 2007-05-17
JP2014167026A (ja) 2014-09-11
HUP9902194A3 (en) 2000-03-28
ID18352A (id) 1998-04-02
BR9709271A (pt) 1999-08-10
GB9709761D0 (en) 1997-07-09
ATE222105T1 (de) 2002-08-15
NO327801B1 (no) 2009-09-28
ES2182079T3 (es) 2003-03-01
DE69714739D1 (de) 2002-09-19
HRP970299B1 (en) 2001-12-31
EP0907364B1 (en) 2002-08-14
CZ388098A3 (cs) 1999-02-17
IL127222A0 (en) 2000-06-01
JP5888549B2 (ja) 2016-03-22
EG24118A (en) 2008-07-06
JP2006152006A (ja) 2006-06-15
CN1511532A (zh) 2004-07-14
HU225152B1 (en) 2006-07-28
JP2000511170A (ja) 2000-08-29
DE69714739T2 (de) 2003-05-15
AR003662A1 (es) 1998-09-09
SI0907364T1 (en) 2003-02-28
WO1997045124A1 (en) 1997-12-04
NO985539L (no) 1998-11-27

Similar Documents

Publication Publication Date Title
MY120120A (en) Sustained release pharmaceutical compositions of thiazepine derivatives.
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
DE69113155D1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3-one-derivate und verfahren zu ihrer herstellung.
ID25628A (id) Senyawa-senyawa baru
FI970526L (fi) Estra-1,3,5(10)-trieenijohdannaiset, niiden valmistusmenetelmät sekä näitä yhdisteitä sisältävät farmaseuttiset koostumukset
HUP9902271A3 (en) Casting form for casting of base of dentistry modell
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
HUP0100024A3 (en) Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
NO20000771D0 (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BG105204A (en) Salts of paroxetine
MX9804828A (es) Benzotiazolona etanaminas biologicamente activas.
RU95107655A (ru) Глюкопиранозидбензотиофены, способ получения, фармацевтическая композиция
HUP0204430A3 (en) Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives, the obtained new compounds and pharmaceutical compositions containing thereof
IL99123A0 (en) Pharmaceutical compositions for treatment of bone wasting diseases,comprising estrogen derivatives
HU9600758D0 (en) Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
HUP0202371A3 (en) Diacylhydrazine derivatives, process for producing them, use of these derivatives for producing of pharmaceutical compositions and pharmaceutical compositions
IS2338B (is) Nýjar morfólínafleiður, aðferð til framleiðslu þeirra og lyfjablöndur sem innihalda þessar afleiður
BG104424A (en) Pseudopolymorphic forms of 2-[2-[4-[bis(4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
ATE215941T1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen